Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

几十年来，医疗界一直在寻找治疗肥胖症的有效药物，直到GLP-1的出现。它还有个拗口的名字：胰高血糖素样肽-1。这是一种存在于肠道中的多肽，能够通过增强胰岛素分泌的方式抑制高血糖素分泌，从而降低血糖。

导读在医疗领域，GLP-1（胰高血糖素样肽-1）药物正逐步超出传统减肥药物的范畴。          事实上，科学家发现，这类药物不仅在帮助人们减轻体重方面效果显著，更在酒精成瘾、帕金森病等多种疾病的治疗中展现出广泛的临床价值。

A study highlights that GLP-1 RAs are linked to a reduced risk of cirrhosis in patients with MASLD and diabetes. Learn more ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

在2024年拉斯克临床医学研究奖的三位得主中，洛克菲勒大学的科学家Svetlana ...

Discover the potential of GLP-1 medications like Ozempic and Mounjaro in treating a wide range of conditions, from diabetes to addiction.

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

People who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be way less likely to die from ...

For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, ...

This helps in reducing calorie intake, which, when combined with lifestyle changes like diet and exercise, can lead to ...

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.